Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

 
• By Elizabeth Orr

The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.

Physician holding tablet in front of brain scan imagery.
• Source: Shutterstock

More from Business

More from Medtech Insight